Biomea Fusion (BMEA) Competitors $1.67 +0.02 (+1.21%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. RNAC, ADCT, AVTE, TSVT, TNXP, ANNX, TKNO, FHTX, CMPS, and RCKTShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Cartesian Therapeutics (RNAC), ADC Therapeutics (ADCT), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Tonix Pharmaceuticals (TNXP), Annexon (ANNX), Alpha Teknova (TKNO), Foghorn Therapeutics (FHTX), COMPASS Pathways (CMPS), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Its Competitors Cartesian Therapeutics ADC Therapeutics Aerovate Therapeutics 2seventy bio Tonix Pharmaceuticals Annexon Alpha Teknova Foghorn Therapeutics COMPASS Pathways Rocket Pharmaceuticals Biomea Fusion (NASDAQ:BMEA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Which has stronger earnings and valuation, BMEA or RNAC? Cartesian Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$138.43M-$3.55-0.45Cartesian Therapeutics$38.91M7.39-$77.42M-$52.83-0.21 Do analysts rate BMEA or RNAC? Biomea Fusion currently has a consensus target price of $21.40, suggesting a potential upside of 1,250.16%. Cartesian Therapeutics has a consensus target price of $40.67, suggesting a potential upside of 267.19%. Given Biomea Fusion's stronger consensus rating and higher probable upside, research analysts plainly believe Biomea Fusion is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility and risk, BMEA or RNAC? Biomea Fusion has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Do insiders and institutionals hold more shares of BMEA or RNAC? 96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor BMEA or RNAC? In the previous week, Biomea Fusion had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 0 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.87 beat Biomea Fusion's score of 1.02 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biomea Fusion Positive Cartesian Therapeutics Very Positive Is BMEA or RNAC more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -197.71% -134.84% Cartesian Therapeutics N/A N/A -7.01% SummaryCartesian Therapeutics beats Biomea Fusion on 8 of the 15 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.55M$2.90B$5.50B$9.03BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-0.4521.4127.5220.10Price / SalesN/A279.21397.84108.06Price / CashN/A41.4736.1356.90Price / Book1.127.457.985.65Net Income-$138.43M-$55.05M$3.16B$248.47M7 Day Performance-20.35%2.83%1.91%2.80%1 Month Performance-36.35%5.56%4.17%5.62%1 Year Performance-63.56%6.39%35.76%21.20% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion2.7615 of 5 stars$1.67+1.2%$21.40+1,181.4%-62.8%$62.74MN/A-0.4750RNACCartesian Therapeutics2.1576 of 5 stars$10.39-2.7%$41.25+297.0%-27.9%$269.66M$34.17M-0.2064Positive NewsADCTADC Therapeutics1.6782 of 5 stars$2.69-0.7%$7.75+188.1%-19.0%$266.79M$70.84M-1.86310AVTEAerovate TherapeuticsN/A$9.19-0.6%N/A-82.4%$266.37MN/A-3.0720High Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440TNXPTonix Pharmaceuticals2.5915 of 5 stars$35.98+3.1%$585.00+1,525.9%-52.3%$264.81M$10.09M-0.0250ANNXAnnexon2.264 of 5 stars$2.40-0.4%$12.50+420.8%-38.4%$263.30MN/A-2.0360News CoveragePositive NewsTKNOAlpha Teknova3.0395 of 5 stars$4.91-3.9%$8.50+73.1%+313.8%$262.39M$37.74M-10.23240News CoverageFHTXFoghorn Therapeutics2.0494 of 5 stars$4.70-2.9%$12.13+158.0%-9.0%$261.98M$22.60M-3.46120News CoverageCMPSCOMPASS Pathways1.9943 of 5 stars$2.80+1.1%$17.00+507.1%-43.3%$261.97MN/A-1.41120High Trading VolumeRCKTRocket Pharmaceuticals4.8905 of 5 stars$2.45-3.2%$18.60+659.2%-85.4%$261.63MN/A-0.93240Trending News Related Companies and Tools Related Companies RNAC Alternatives ADCT Alternatives AVTE Alternatives TSVT Alternatives TNXP Alternatives ANNX Alternatives TKNO Alternatives FHTX Alternatives CMPS Alternatives RCKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMEA Stock Alerts